ClearPoint Neuro, Inc.

NasdaqCM:CLPT Stock Report

Market Cap: US$415.7m

ClearPoint Neuro Management

Management criteria checks 4/4

ClearPoint Neuro's CEO is Joe Burnett, appointed in Nov 2017, has a tenure of 7.17 years. total yearly compensation is $2.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.91% of the company’s shares, worth $3.77M. The average tenure of the management team and the board of directors is 3.9 years and 6.3 years respectively.

Key information

Joe Burnett

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage25.9%
CEO tenure7.2yrs
CEO ownership0.9%
Management average tenure3.9yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

CEO Compensation Analysis

How has Joe Burnett's remuneration changed compared to ClearPoint Neuro's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$2mUS$518k

-US$22m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$2mUS$494k

-US$16m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$1mUS$445k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$784kUS$435k

-US$7m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$864kUS$366k

-US$6m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$515kUS$360k

-US$6m

Compensation vs Market: Joe's total compensation ($USD2.00M) is about average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Burnett (47 yo)

7.2yrs

Tenure

US$1,995,337

Compensation

Mr. Joseph Michael Burnett, also known as Joe, has been Chief Executive Officer, President and Director of ClearPoint Neuro, Inc. since November 7, 2017. Mr. Burnett has spent his entire career in medical...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Burnett
President7.2yrsUS$2.00m0.91%
$ 3.8m
Danilo D'Alessandro
Chief Financial Officer4yrsUS$930.98k0.19%
$ 775.2k
Jeremy Stigall
Chief Business Officer2yrsUS$838.49kno data
Mazin Sabra
Chief Operating Officer2.3yrsno data0.14%
$ 572.3k
Ellisa Cholapranee
General Counsel & Secretary3.8yrsno datano data
Jacqueline Keller
Vice President of Marketing5.2yrsno datano data

3.9yrs

Average Tenure

41.5yo

Average Age

Experienced Management: CLPT's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Burnett
President7.2yrsUS$2.00m0.91%
$ 3.8m
R. Fletcher
Independent Chairman of the Board7.7yrsUS$227.62k0.34%
$ 1.4m
B. Johnson
Independent Director5.3yrsUS$189.99k0.14%
$ 566.7k
Lynnette Fallon
Independent Director3.5yrsUS$202.49k0.11%
$ 452.2k
Pascal E. Girin
Independent Director10.3yrsUS$192.65k0.27%
$ 1.1m
Linda Liau
Independent Director3.2yrsUS$182.49k0.11%
$ 471.6k
Timothy Richards
Independent Director10.8yrsUS$194.75k0.24%
$ 984.8k
Matthew Klein
Director4.8yrsUS$174.99k0.11%
$ 443.4k

6.3yrs

Average Tenure

64yo

Average Age

Experienced Board: CLPT's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:17
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ClearPoint Neuro, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Kyle BauserB. Riley Securities, Inc.
Sally YanchusBrookline Capital Markets